One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."

But there's a much better move you can make to get in front of these big moves today.

Michael J. Holston net worth and biography

Michael Holston Biography and Net Worth

EVP of Merck & Co., Inc.

Mike Holston is Senior Vice President, General Counsel and Secretary, of GE. In this role, Mike leads the company’s global legal, compliance and ethics, corporate secretary and environment health & safety organizations.

Mike joined GE from Merck & Co., Inc. where he most recently served as Executive Vice President and General Counsel. Before joining Merck, Mike served as Executive Vice President, General Counsel and Board Secretary of Hewlett-Packard Company.

Earlier in his career, Mike served as a prosecutor in the criminal division of the U.S. Attorney's Office for the Eastern District of Pennsylvania; he also was a partner at Morgan Lewis and was a managing partner at Drinker Biddle & Reath.

What is Michael J. Holston's net worth?: The estimated net worth of Michael J. Holston is at least $7.08 million as of February 14th, 2024. Mr. Holston owns 56,284 shares of Merck & Co., Inc. stock worth more than $7,079,402 as of April 19th. This net worth estimate does not reflect any other assets that Mr. Holston may own. Learn More about Michael J. Holston's net worth.
How do I contact Michael J. Holston?: The corporate mailing address for Mr. Holston and other Merck & Co., Inc. executives is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. Merck & Co., Inc. can also be reached via phone at (908) 740-4000 and via email at [email protected]. Learn More on Michael J. Holston's contact information.
Has Michael J. Holston been buying or selling shares of Merck & Co., Inc.?: Michael J. Holston has not been actively trading shares of Merck & Co., Inc. within the last three months. Learn More on Michael J. Holston's trading history.
Who are Merck & Co., Inc.'s active insiders?: Merck & Co., Inc.'s insider roster includes Sanat Chattopadhyay (Insider), Frank Clyburn (EVP), Robert Davis (CFO), Richard Deluca (EVP), Kenneth Frazier (Insider), Julie Gerberding (EVP), Clark Golestani (EVP), Michael Holston (EVP), Rita Karachun (VP), Caroline Litchfield (CFO), Steven Mizell (EVP), Johannes Oosthuizen (Insider), Joseph Romanelli (Insider), Ashley Watson (SVP), and Wendell Weeks (Director). Learn More on Merck & Co., Inc.'s active insiders.
Are insiders buying or selling shares of Merck & Co., Inc.?: During the last year, Merck & Co., Inc. insiders bought shares 1 times. They purchased a total of 3 shares worth more than $341.04. During the last year, insiders at the sold shares 11 times. They sold a total of 460,551 shares worth more than $53,354,373.87. The most recent insider tranaction occured on February, 13th when insider Joseph Romanelli sold 1,000 shares worth more than $124,890.00. Insiders at Merck & Co., Inc. own 0.2% of the company. Learn More about insider trades at Merck & Co., Inc..
Information on this page was last updated on 2/13/2024.

Michael J. Holston Insider Trading History at Merck & Co., Inc.

Michael J. Holston Buying and Selling Activity at Merck & Co., Inc.

Merck & Co., Inc. Company Overview

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.

Today's Range

Now: $125.78

$124.89

$126.12

50 Day Range

MA: $126.17

$120.54

$131.95

2 Week Range

Now: $125.78

$99.14

$133.10

Volume

8,385,425 shs

Average Volume

8,316,512 shs

Market Capitalization

$318.60 billion

P/E Ratio

898.43

Dividend Yield

2.46%

Beta

0.38

Strange new buyer driving up gold

From Stansberry Research | Ad